Eli Lilly, the maker of blockbuster weight loss ... aim to build on the weight-loss success of Zepbound, including a pill in development called orforglipron that’s expected to have results ...
Eli Lilly has suffered a major setback after the US regulator rejected its rheumatoid arthritis pill, baricitinib, sending the company’s share price plummeting. Lilly received a letter from the ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas, and more. To get it in your ...
Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by growth of new products such as Trulicity, Taltz and Jardiance. However this upbeat story has been spoilt by a ...
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results